Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.

BMC cancer·2015
Same author

Leukemia. Q&A highlights.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2007
Same author

Chronic myeloid leukemia in 2007.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2007
Same author

Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2007
Same author

Monitoring your patients with chronic myeloid leukemia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2006

Related Experiment Video

Updated: Jul 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Chronic myeloid leukemia in 2007.

Jolynn Sessions1

  • 1Emory University Hospital, Atlanta, GA, USA.

Journal of Managed Care Pharmacy : JMCP
|November 27, 2007
PubMed
Summary

Chronic myeloid leukemia (CML) is driven by the BCR-ABL oncogene. Sensitive molecular testing, like quantitative PCR, is crucial for monitoring treatment response and predicting prognosis in CML patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Chronic myeloid leukemia (CML) is a stem cell cancer accounting for 14% of leukemias.
  • Effective kinase inhibitors targeting BCR-ABL have significantly reduced CML mortality.
  • Understanding CML pathogenesis is key to improving patient outcomes.

Purpose of the Study:

  • Review the molecular pathogenesis of CML.
  • Describe the clinical course and diagnosis of CML.
  • Explain the role of cytogenetic and molecular testing in CML management.

Main Methods:

  • Review of CML molecular pathogenesis.
  • Analysis of clinical course and diagnostic methods.
  • Evaluation of laboratory tests: CBC, cytogenetics, FISH, and quantitative PCR.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jul 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Main Results:

  • CML arises from the Philadelphia chromosome translocation, creating the constitutively active BCR-ABL oncoprotein.
  • Kinase inhibitors are effective in the chronic phase, but resistance occurs.
  • Quantitative PCR offers the highest sensitivity (detecting 10^5 leukemic cells) for monitoring treatment response.

Conclusions:

  • Sensitive monitoring of CML disease burden is vital with kinase inhibitor therapy.
  • Regular testing improves prognosis prediction and allows timely therapy adjustments.
  • Early detection of treatment failure enables proactive management and prevents disease progression.